Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 13:20 save search
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
Published: 2023-08-16 (Crawled : 13:20) - biospace.com/
ELEV | $3.79 -5.49% -5.8% 990K
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 1.1%
C: -5.0%
eo-3021 trial
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -0.75%
H: 2.79%
C: 1.59%
favorable cancer pancreatic tumor trial therapy
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 0.18%
H: 1.98%
C: -0.28%
covid-19 vaccine leukemia trial phase 2
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 4.67%
H: 2.68%
C: 1.79%
health approval canada trial therapeutics phase 2
Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
PLSH | $0.19 -35.6% 100
|
n/a
|
| O: -21.26%
H: 6.67%
C: 0.0%
management life sciences trial
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
Published: 2023-07-17 (Crawled : 13:20) - globenewswire.com
IMMX | $2.21 0.0% 64K
|
|
| O: -3.49%
H: 22.62%
C: -2.71%
imx-110 readout positive cancer biopharma ongoing trial
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.62%
H: 0.0%
C: -1.54%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.67%
H: 1.42%
C: 1.06%
update trial therapeutics
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
Published: 2023-07-10 (Crawled : 13:20) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 0.0%
H: 2.48%
C: 0.84%
update ongoing trial therapeutics phase 2
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
Published: 2023-06-28 (Crawled : 13:20) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 2.62%
H: 24.49%
C: 19.39%
quantum arm leap update ongoing trial therapeutics
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
Published: 2023-06-26 (Crawled : 13:20) - globenewswire.com
IMMX | $2.21 0.0% 64K
|
|
| O: -2.3%
H: 1.96%
C: -4.71%
nxc-201 fda biopharma meeting trial
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Published: 2023-06-26 (Crawled : 13:20) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 3.9%
H: 0.0%
C: -3.06%
sti-1558 covid-19 treatment trial
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Published: 2023-06-22 (Crawled : 13:20) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.78%
H: 28.38%
C: 13.51%
trial platform
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
Published: 2023-06-12 (Crawled : 13:20) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 1.06%
H: 5.73%
C: 3.81%
breast cancer treatment her2- trial
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
Published: 2023-06-07 (Crawled : 13:20) - globenewswire.com
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 7.16%
H: 5.23%
C: -2.57%
bx1000 positive trial results phase 2
Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy Interim 6-month Data Expected in the First Quarter of 2024
Published: 2023-06-07 (Crawled : 13:20) - biospace.com/
OCUL | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
|
| O: 0.39%
H: 0.91%
C: -3.39%
ocular expected treatment trial diabetic
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0
Published: 2023-06-05 (Crawled : 13:20) - biospace.com/
CWBR | $0.9003 -11.88% 360
|
Health Technology
|
| O: 6.64%
H: 8.85%
C: -11.48%
positive trial results
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
Published: 2023-05-31 (Crawled : 13:20) - globenewswire.com
BSTG 4 | $4.03 67.25% 4.5K
|
Manufacturing
| Email alert
Add to watchlist
disease trial study initiated
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Published: 2023-05-19 (Crawled : 13:20) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K
|
|
| O: 0.63%
H: 0.0%
C: -8.72%
can-3110 cell ongoing meeting trial therapeutics therapy
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
Published: 2023-05-10 (Crawled : 13:20) - biospace.com/
AADI | $1.835 1.94% 1.91% 140K
|
Manufacturing
|
| O: -5.65%
H: 3.12%
C: -11.61%
bioscience update tumor trial financial results
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-05-09 (Crawled : 13:20) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: -1.99%
H: 9.04%
C: 4.97%
breast cancer meeting trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.